191 related articles for article (PubMed ID: 22220266)
1. Incidence of acute myeloid leukemia after breast cancer.
Valentini CG; Fianchi L; Voso MT; Caira M; Leone G; Pagano L
Mediterr J Hematol Infect Dis; 2011; 3(1):e2011069. PubMed ID: 22220266
[TBL] [Abstract][Full Text] [Related]
2. Risk for the development of treatment-related acute myelocytic leukemia and myelodysplastic syndrome among patients with breast cancer: review of the literature and the National Surgical Adjuvant Breast and Bowel Project experience.
Smith RE
Clin Breast Cancer; 2003 Oct; 4(4):273-9. PubMed ID: 14651772
[TBL] [Abstract][Full Text] [Related]
3. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
4. The incidence of secondary leukemias.
Leone G; Mele L; Pulsoni A; Equitani F; Pagano L
Haematologica; 1999 Oct; 84(10):937-45. PubMed ID: 10509043
[TBL] [Abstract][Full Text] [Related]
5. Acute myeloid leukemia after adjuvant breast cancer therapy in older women: understanding risk.
Patt DA; Duan Z; Fang S; Hortobagyi GN; Giordano SH
J Clin Oncol; 2007 Sep; 25(25):3871-6. PubMed ID: 17664457
[TBL] [Abstract][Full Text] [Related]
6. [Therapy-related hematologic neoplasias after breast cancer. Epidemiologic, etiologic and cytogenetic aspects and new risk factors according to published data and own results].
Haase D; Hanf V; Schulz T
Med Klin (Munich); 2004 Sep; 99(9):506-17. PubMed ID: 15372180
[TBL] [Abstract][Full Text] [Related]
7. Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience.
Smith RE; Bryant J; DeCillis A; Anderson S;
J Clin Oncol; 2003 Apr; 21(7):1195-204. PubMed ID: 12663705
[TBL] [Abstract][Full Text] [Related]
8. Increased risk of acute leukemia after adjuvant chemotherapy for breast cancer: a population-based study.
Chaplain G; Milan C; Sgro C; Carli PM; Bonithon-Kopp C
J Clin Oncol; 2000 Aug; 18(15):2836-42. PubMed ID: 10920131
[TBL] [Abstract][Full Text] [Related]
9. Acute myeloid leukemia and myelodysplastic syndrome after adjuvant chemotherapy: A population-based study among older breast cancer patients.
Rosenstock AS; Niu J; Giordano SH; Zhao H; Wolff AC; Chavez-MacGregor M
Cancer; 2018 Mar; 124(5):899-906. PubMed ID: 29236294
[TBL] [Abstract][Full Text] [Related]
10. Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer.
Le Deley MC; Suzan F; Cutuli B; Delaloge S; Shamsaldin A; Linassier C; Clisant S; de Vathaire F; Fenaux P; Hill C
J Clin Oncol; 2007 Jan; 25(3):292-300. PubMed ID: 17159192
[TBL] [Abstract][Full Text] [Related]
11. Leukemia incidence following primary breast carcinoma treatment.
Kaplan HG; Malmgren JA; Atwood M
Cancer; 2004 Oct; 101(7):1529-36. PubMed ID: 15378478
[TBL] [Abstract][Full Text] [Related]
12. Leukemia following chemotherapy for breast cancer.
Curtis RE; Boice JD; Moloney WC; Ries LG; Flannery JT
Cancer Res; 1990 May; 50(9):2741-6. PubMed ID: 2328500
[TBL] [Abstract][Full Text] [Related]
13. Leukemia risk after adjuvant treatment of early breast cancer.
Balduzzi A; Castiglione-Gertsch M
Womens Health (Lond); 2005 Jul; 1(1):73-85. PubMed ID: 19803948
[TBL] [Abstract][Full Text] [Related]
14. Mammography screening: A major issue in medicine.
Autier P; Boniol M
Eur J Cancer; 2018 Feb; 90():34-62. PubMed ID: 29272783
[TBL] [Abstract][Full Text] [Related]
15. Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511).
Freedman RA; Seisler DK; Foster JC; Sloan JA; Lafky JM; Kimmick GG; Hurria A; Cohen HJ; Winer EP; Hudis CA; Partridge AH; Carey LA; Jatoi A; Klepin HD; Citron M; Berry DA; Shulman LN; Buzdar AU; Suman VJ; Muss HB
Breast Cancer Res Treat; 2017 Jan; 161(2):363-373. PubMed ID: 27866278
[TBL] [Abstract][Full Text] [Related]
16. Risk of marrow neoplasms after adjuvant breast cancer therapy: the national comprehensive cancer network experience.
Wolff AC; Blackford AL; Visvanathan K; Rugo HS; Moy B; Goldstein LJ; Stockerl-Goldstein K; Neumayer L; Langbaum TS; Theriault RL; Hughes ME; Weeks JC; Karp JE
J Clin Oncol; 2015 Feb; 33(4):340-8. PubMed ID: 25534386
[TBL] [Abstract][Full Text] [Related]
17. Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy: the University of Texas M.D. Anderson Cancer Center experience.
Diamandidou E; Buzdar AU; Smith TL; Frye D; Witjaksono M; Hortobagyi GN
J Clin Oncol; 1996 Oct; 14(10):2722-30. PubMed ID: 8874333
[TBL] [Abstract][Full Text] [Related]
18. Risk of leukemia after chemotherapy and radiation treatment for breast cancer.
Curtis RE; Boice JD; Stovall M; Bernstein L; Greenberg RS; Flannery JT; Schwartz AG; Weyer P; Moloney WC; Hoover RN
N Engl J Med; 1992 Jun; 326(26):1745-51. PubMed ID: 1594016
[TBL] [Abstract][Full Text] [Related]
19. Acute myeloid leukemia in patients previously diagnosed with breast cancer: experience of the GIMEMA group.
Pagano L; Pulsoni A; Mele L; Tosti ME; Cerri R; Visani G; Melillo L; Candoni A; Clavio M; Nosari A; Petti MC; Martino B; Mele A; Levis A; Allione B; Almici C; Equitani F; Leone G; Mandelli F;
Ann Oncol; 2001 Feb; 12(2):203-7. PubMed ID: 11300325
[TBL] [Abstract][Full Text] [Related]
20. Risk of secondary myeloid leukemia and myelodysplastic syndrome following standard-dose chemotherapy or high-dose chemotherapy with stem cell support in patients with potentially curable malignancies.
Kollmannsberger C; Hartmann JT; Kanz L; Bokemeyer C
J Cancer Res Clin Oncol; 1998; 124(3-4):207-14. PubMed ID: 9619748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
